Biological Therapy for Inflammatory Bowel Disease in Children

다국어 초록 (Multilingual Abstract)

The pathogenesis of inflammatory bowel diseases is not very well understood; it is currently thought to be caused by the interaction between genetic factors, environmental factors, intestinal microbes, and immune factors. Biological agents such as anti-tumor necrosis factor (anti-TNF) are widely being used as therapeutic agents. Infliximab, a chimeric monoclonal IgG1 antibody against tumor necrosis factor, has been demonstrated to have an effect in the induction and maintenance of remission in Crohn's disease in children. The effects of biological agents, typified by anti-TNFs, in inflammatory bowel disease in children; the recent concern on the administration of biological agents in combination with immunomodulators; and 'Top-down’ therapy are some of the topics covered in this review.

참고문헌 (Reference)

1 서정기, "소아기에 발병하는 염증성장질환(IBD)은 성인 IBD와 다른 질환인가? - 조기발병 소아 IBD의 역학적, 임상적, 유전학적 특성 및 치료 시 고려 사항-" 대한소아소화기영양학회 14 (14): 1-25, 2011

2 Van Assche G, "Withdrawal of immunosuppression in Crohn disease treated with scheduled infliximab maintenance: a randomized trial" 134 : 1861-1868, 2008

3 Melmed GY, "The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all" 8 : 655-659, 2010

4 Siegel CA, "Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn disease: a meta- analysis" 7 : 874-881, 2009

5 Toruner M, "Risk factors for opportunistic infections in patients with inflammatory bowel disease" 134 : 929-936, 2008

6 Oussalah A, "Predictors of infliximab failure after azathioprine withdrawal in Crohn disease treated with combination therapy" 105 : 1142-1149, 2010

7 Hyams JS, "Outcome following infliximab therapy in children with ulcerative colitis" 105 : 1430-1436, 2010

8 Hanauer SB, "Maintenance infliximab for Crohn disease: the ACCENT I randomised trial" 359 : 1541-1549, 2002

9 Sandborn WJ, "Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn disease" 117 : 527-535, 1999

10 Colombel JF, "Infliximab, azathioprine, or combination therapy for Crohn disease" 1362 : 1383-1395, 2010

11 Rutgeerts P, "Infliximab for induction and maintenance therapy for ulcerative colitis" 353 : 2462-2476, 2005

12 Romeo E, "Infliximab As a First Choice Therapy in Children with Newly Diagnosed Crohn’s Disease (CD) Promotes Long-Term Sustained Remission and Alters the Course of the Disease" 130 (130): 11-, 2006

13 Hyams JS, "Induction and maintenance infliximab therapy for the treatment of moderate to severe Crohn's disease in children" 132 : 863-873, 2007

14 Thayu M, "Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study" 6 : 1378-1384, 2008

15 Mowat C, "Guidelines for the management of inflammatory bowel disease in adults" 60 : 571-607, 2011

16 Munkholm P, "Frequency of glucocorticoid resistance and dependency in Crohn disease" 35 : 360-362, 1994

17 D'Haens G, "Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn disease: an open randomised trial" 371 : 660-667, 2008

18 Sandborn WJ, "Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab" 137 : 1250-1260, 2009

19 Rutgeerts P, "Biological therapies for inflammatory bowel disease" 136 : 1182-1197, 2009

20 Van Moerkercke W, "Anti-TNFα Induced Severe Arthralgia as a Manifestation of Autoimmunity?" 138 (138): 60-61, 2010

21 Kotlyar DS, "A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease" 9 : 36-41, 2011